Superficial femoral—popliteal veins and reversed saphenous veins as primary femoropopliteal bypass grafts: A randomized comparative study

Vascular reconstruction with the superficial femoral vein following major oncologic resection

“…They reported superior patency rates in the first two years, when compared to the traditional greater saphenous vein (GSV) conduits. [36] After an initial learning phase, their results were even better, and 3-year patency rates were above 80% (compared to 67% for GSV grafts). In addition, they reported no significant late morbidity.…”

Long-term results of the treatment of aortic graft infection by in situ replacement with femoral popliteal vein grafts

“…In addition to NAIS procedures for AGI, we and others have demonstrated the beneficial features of this large caliber vein graft in multiple vascular beds. 9,[28][29][30][31] Acute venous morbidity resulting in the need for fasciotomy remains a problem with harvesting FPVs in some patients. In a previous report, we demonstrated that preexisting advanced lower extremity ischemia, concomitant harvest of ipsilateral GSV, and excessive crystalloid administration during operation were independent risk factors for compartment syndrome and the need for fasciotomy.…”

Adjunctive use of the superficial femoral vein for vascular reconstructions

“…Although our results corroborate and expand on existing literature, we intended to also demonstrate some unconventional uses of the SFV that have rarely been studied. Some of the earliest evidence supporting the use of SFV came from three studies conducted by Schulman et al [1][2][3] They focused on the use of SFV for femoral-popliteal bypass grafts. The main tenets guiding their operative technique included profunda vein preservation and short, single-segment conduits.…”

“…Schulman et al [1][2][3] demonstrated that the SFV could be used as an alternate conduit for femoral-popliteal arterial bypass with patency rates comparable to the great saphenous vein (GSV). Another common use for the SFV has been in constructing the neoaortoiliac system to treat prosthetic aortofemoral graft infections.…”